For the year ending 2025-12-31, NXGL had -$749K decrease in cash & cash equivalents over the period. -$1,379K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Realized gain on investment in marketable securities | 0 |
| Change in fair value of contingent consideration | 0 |
| Net loss | -2,893 |
| Depreciation and amortization | 450 |
| Change in fair value of warrant liability | -118 |
| Amortization of right of use asset | 290 |
| Gain in spin-off of nexgelrx | 162 |
| Accounts receivable, net | -260 |
| Inventory | 360 |
| Prepaid expenses and other current assets | -127 |
| Accounts payable | -38 |
| Accounts payable related party | 35 |
| Accrued expenses and other current liabilities | 150 |
| Partnership advance | 731 |
| Deferred revenue | -177 |
| Operating lease liability | -260 |
| Share-based compensation | 654 |
| Net cash used in operating activities | -1,311 |
| Investment in subsidiary | 0 |
| Proceeds from sales of marketable securities | 0 |
| Purchases of equipment | 68 |
| Net cash provided by (used in) investing activities | -68 |
| Proceeds from non-controlling interest | 0 |
| Proceeds from margin line of credit | 0 |
| Payment of contingent consideration | 177 |
| Proceeds from rights offering | 963 |
| Principal payments of notes payable | 97 |
| Principal payment of financing lease liability | 59 |
| Net cash provided by financing activities | 630 |
| Net increase (decrease) in cash () | -749 |
| Net increase (decrease) in cash () | -749 |
| Cash and restricted cash beginning of year | 1,807 |
| Cash and restricted cash end of year | 1,058 |
NEXGEL, INC. (NXGL)
NEXGEL, INC. (NXGL)